For the quarter ended September 2025, Hologic (HOLX) reported revenue of $1.05 billion, up 6.2% over the same period last year. EPS came in at $1.13, compared to $1.01 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $1.03 billion, representing a surprise of +1.49%. The company delivered an EPS surprise of +2.73%, with the consensus EPS estimate being $1.10.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Hologic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- GYN surgical: $172.5 million versus $175.86 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.2% change.
- Revenues- Diagnostics- Molecular diagnostics: $323.1 million compared to the $326.94 million average estimate based on three analysts. The reported number represents a change of +1.2% year over year.
- Revenues- Diagnostics- Blood screening: $7.9 million versus $4.99 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.
- Revenues- Breast health- Breast imaging: $291.5 million versus the three-analyst average estimate of $286.03 million. The reported number represents a year-over-year change of -0.7%.
- Revenues- Total Diagnostics: $454.1 million compared to the $448.39 million average estimate based on three analysts. The reported number represents a change of +2.4% year over year.
- Revenues- Skeletal health: $29.2 million versus $29.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +129.9% change.
- Revenues- Diagnostics- Cytology and perinatal: $123.1 million compared to the $116.46 million average estimate based on three analysts. The reported number represents a change of +5.7% year over year.
- Revenues- Total Breast health: $393.7 million versus the three-analyst average estimate of $379.38 million. The reported number represents a year-over-year change of +4.9%.
- Revenues- Breast health- Interventional breast solutions: $102.2 million compared to the $93.35 million average estimate based on three analysts. The reported number represents a change of +24.5% year over year.
- Revenues- Service and other: $214.4 million compared to the $206.32 million average estimate based on two analysts. The reported number represents a change of +7.2% year over year.
- Revenues- Product: $835.1 million compared to the $825.89 million average estimate based on two analysts. The reported number represents a change of +6% year over year.
View all Key Company Metrics for Hologic here>>>
Shares of Hologic have returned +8.3% over the past month versus the Zacks S&P 500 composite's +2.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
